表紙
市場調査レポート

全身性紅斑性狼瘡 (SLE):パイプライン製品の分析

Systemic Lupus Erythematosus - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 264101
出版日 ページ情報 英文 367 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
全身性紅斑性狼瘡 (SLE):パイプライン製品の分析 Systemic Lupus Erythematosus - Pipeline Review, H1 2016
出版日: 2016年05月11日 ページ情報: 英文 367 Pages
概要

全身性紅斑性狼瘡 (SLE) は、長期にわたる慢性的な炎症性疾患で、体内の面寝機システムが健康な組織を攻撃するという自己免疫疾患です。そのため、皮膚や関節、腎臓、脳などの器官が影響を受けます。はっきりとした原因は分かっていませんが、様々な要因が遺伝、環境、性、ホルモンなどの疾患と関係しています。 症侯は様々で、時間とともに変化しますが、一般的なものとして重度の疲労感、関節の痛みや腫れ、頭痛、蝶形紅斑と呼ばれる頬や鼻の発疹、抜け毛、貧血などがあります。

当レポートでは、全身性紅斑性狼瘡 (SLE) の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

全身性紅斑性狼瘡の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

全身性紅斑性狼瘡:企業で開発中の治療薬

全身性紅斑性狼瘡:大学/機関で研究中の治療薬

全身性紅斑性狼瘡:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

全身性紅斑性狼瘡:企業で開発中の製品

全身性紅斑性狼瘡:大学/機関で研究中の製品

全身性紅斑性狼瘡の治療薬開発に従事している企業

  • 4SC AG
  • AbbVie Inc.
  • Ablynx NV
  • ACEA Biosciences, Inc.
  • Actelion Ltd
  • AiCuris GmbH & Co. KG
  • Alpha Cancer Technologies Inc.
  • Amgen Inc.
  • Anthera Pharmaceuticals, Inc.
  • arGEN-X BV
  • Argos Therapeutics, Inc.
  • アステラス製薬
  • Baxalta Incorporated
  • Biogen, Inc.
  • Biotest AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cellular Biomedicine Group, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • エーザイ
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genosco
  • Genovax S.r.l.
  • GlaxoSmithKline Plc
  • ImmuNext, Inc.
  • Immungenetics AG
  • Immunomedics, Inc.
  • Immupharma Plc
  • Invion Limited
  • Johnson & Johnson
  • K-Stemcell Co., Ltd.
  • Kadmon Corporation, LLC
  • Karyopharm Therapeutics, Inc.
  • Kolltan Pharmaceuticals, Inc.
  • Lead Discovery Center GmbH
  • LSK BioPartners, Inc.
  • MacroGenics, Inc.
  • MedAnnex Ltd
  • MedImmune, LLC
  • Merck KGaA
  • Millennium Pharmaceuticals, Inc.
  • 田辺三菱製薬
  • Neovacs SA
  • Nippon Chemiphar Co., Ltd.
  • Plexxikon Inc.
  • Principia Biopharma Inc.
  • RedHill Biopharma Ltd.
  • Redx Pharma Plc
  • Resolve Therapeutics, LLC
  • Sanofi
  • Sarepta Therapeutics, Inc.
  • SBI Biotech Co., Ltd.
  • Seattle Genetics, Inc.
  • Stemline Therapeutics, Inc.
  • 武田薬品工業
  • TheraMAB LLC
  • Therapix Biosciences Ltd
  • UCB S.A.
  • Xencor, Inc.
  • XTL Biopharmaceuticals Ltd.

全身性紅斑性狼瘡:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

全身性紅斑性狼瘡:最近のパイプライン動向

全身性紅斑性狼瘡:休止中のプロジェクト

全身性紅斑性狼瘡:開発が中止された製品

全身性紅斑性狼瘡:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7998IDB

Summary

Global Markets Direct's, 'Systemic Lupus Erythematosus - Pipeline Review, H1 2016', provides an overview of the Systemic Lupus Erythematosus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus
  • The report reviews pipeline therapeutics for Systemic Lupus Erythematosus by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Systemic Lupus Erythematosus therapeutics and enlists all their major and minor projects
  • The report assesses Systemic Lupus Erythematosus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Systemic Lupus Erythematosus Overview
  • Therapeutics Development
    • Pipeline Products for Systemic Lupus Erythematosus - Overview
    • Pipeline Products for Systemic Lupus Erythematosus - Comparative Analysis
  • Systemic Lupus Erythematosus - Therapeutics under Development by Companies
  • Systemic Lupus Erythematosus - Therapeutics under Investigation by Universities/Institutes
  • Systemic Lupus Erythematosus - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Systemic Lupus Erythematosus - Products under Development by Companies
  • Systemic Lupus Erythematosus - Products under Investigation by Universities/Institutes
  • Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development
    • 4SC AG
    • AbbVie Inc.
    • Ablynx NV
    • ACEA Biosciences, Inc.
    • Actelion Ltd
    • AiCuris GmbH & Co. KG
    • Alpha Cancer Technologies Inc.
    • Amgen Inc.
    • Anthera Pharmaceuticals, Inc.
    • arGEN-X BV
    • Argos Therapeutics, Inc.
    • Astellas Pharma Inc.
    • Baxalta Incorporated
    • Biogen, Inc.
    • Biotest AG
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Cellular Biomedicine Group, Inc.
    • Chong Kun Dang Pharmaceutical Corp.
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Genosco
    • Genovax S.r.l.
    • GlaxoSmithKline Plc
    • ImmuNext, Inc.
    • Immungenetics AG
    • Immunomedics, Inc.
    • Immupharma Plc
    • Invion Limited
    • Johnson & Johnson
    • K-Stemcell Co., Ltd.
    • Kadmon Corporation, LLC
    • Karyopharm Therapeutics, Inc.
    • Kolltan Pharmaceuticals, Inc.
    • Lead Discovery Center GmbH
    • LSK BioPartners, Inc.
    • MacroGenics, Inc.
    • MedAnnex Ltd
    • MedImmune, LLC
    • Merck KGaA
    • Millennium Pharmaceuticals, Inc.
    • Mitsubishi Tanabe Pharma Corporation
    • Neovacs SA
    • Nippon Chemiphar Co., Ltd.
    • Plexxikon Inc.
    • Principia Biopharma Inc.
    • RedHill Biopharma Ltd.
    • Redx Pharma Plc
    • Resolve Therapeutics, LLC
    • Sanofi
    • Sarepta Therapeutics, Inc.
    • SBI Biotech Co., Ltd.
    • Seattle Genetics, Inc.
    • Stemline Therapeutics, Inc.
    • Takeda Pharmaceutical Company Limited
    • TheraMAB LLC
    • Therapix Biosciences Ltd
    • UCB S.A.
    • Xencor, Inc.
    • XTL Biopharmaceuticals Ltd.
  • Systemic Lupus Erythematosus - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (clarithromycin + clofazimine + rifabutin) - Drug Profile
    • abatacept - Drug Profile
    • ABBV-084 - Drug Profile
    • ABS-11 - Drug Profile
    • AC-058 - Drug Profile
    • ACT-101 - Drug Profile
    • AGS-009 - Drug Profile
    • AIC-284 - Drug Profile
    • ALX-0061 - Drug Profile
    • AMG-557 - Drug Profile
    • AMG-570 - Drug Profile
    • amiselimod hydrochloride - Drug Profile
    • anifrolumab - Drug Profile
    • Annexuzlimab - Drug Profile
    • Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile
    • ARGX-113 - Drug Profile
    • AT-791 - Drug Profile
    • atacicept - Drug Profile
    • baricitinib - Drug Profile
    • BB-004 - Drug Profile
    • belimumab - Drug Profile
    • BIIB-059 - Drug Profile
    • blisibimod - Drug Profile
    • bortezomib - Drug Profile
    • brentuximab vedotin - Drug Profile
    • BT-063 - Drug Profile
    • CC-220 - Drug Profile
    • Cellular Immunotherapy for Autoimmune Diseases and Transplantation - Drug Profile
    • Cellular Immunotherapy for Systemic Lupus Erythematosus and Epstein-Barr Viral Infections - Drug Profile
    • Cenerimod - Drug Profile
    • CKD-506 - Drug Profile
    • CS-20AT04 - Drug Profile
    • dapirolizumab pegol - Drug Profile
    • Drug to Inhibit PAD for Autoimmune Diseases, CNS Disorders and Oncology - Drug Profile
    • E-6446 - Drug Profile
    • edratide - Drug Profile
    • forigerimod acetate - Drug Profile
    • GNKS-356 - Drug Profile
    • GX-101 - Drug Profile
    • HCI-1401 - Drug Profile
    • IGM-001 - Drug Profile
    • IMP-10 - Drug Profile
    • INV-103 - Drug Profile
    • INV-17 - Drug Profile
    • ixazomib citrate - Drug Profile
    • JB-6121 - Drug Profile
    • JBT-101 - Drug Profile
    • JNJ-55920839 - Drug Profile
    • KD-025 - Drug Profile
    • KPT-350 - Drug Profile
    • lulizumab pegol - Drug Profile
    • M-2951 - Drug Profile
    • MGD-010 - Drug Profile
    • milatuzumab - Drug Profile
    • Monoclonal Antibodies to Inhibit IL-3RA for Autoimmune Disorders - Drug Profile
    • Monoclonal Antibody Conjugate to Inhibit TAM RTK for Cancer, Inflammation, Auto immune diseases and Infection - Drug Profile
    • Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Infectious and Metabolic Diseases - Drug Profile
    • Monoclonal Antibody to Inhibit ILT7 for Systemic Lupus Erythematosus - Drug Profile
    • NC-2400 - Drug Profile
    • NCS-613 - Drug Profile
    • PRN-1008 - Drug Profile
    • RCT-18 - Drug Profile
    • RDX-002 - Drug Profile
    • Recombinant Proteins for Systemic Lupus Erythematosus - Drug Profile
    • RO-5461111 - Drug Profile
    • RSLV-132 - Drug Profile
    • RSLV-133 - Drug Profile
    • SAR-113244 - Drug Profile
    • SBI-3150 - Drug Profile
    • SKIO-703 - Drug Profile
    • SM-03 - Drug Profile
    • SM-101 - Drug Profile
    • SM-934 - Drug Profile
    • Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile
    • Small Molecule to Inhibit RORgammat for CNS, Autoimmune and Gastrointestinal Disorders - Drug Profile
    • Small Molecules for Dermatology, Immunology, Metabolic and CNS Disorders - Drug Profile
    • Small Molecules for Respiratory and Immunology - Drug Profile
    • Small Molecules to Inhibit FMS Kinase for Central Nervous System, Gastrointestinal, Immunology and Respiratory Diseases - Drug Profile
    • Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile
    • Stem Cell Therapy for Autoimmune Diseases - Drug Profile
    • Stem Cell Therapy for Cerebral Palsy and Systemic Lupus Erythematosus - Drug Profile
    • Stem Cell Therapy for Musculoskeletal, CNS Disorders, Dermatology, Immunology and Cardiovascular Disease - Drug Profile
    • Synthetic Peptide for Systemic Lupus Erythematosus - Drug Profile
    • Synthetic Peptides for Systemic Lupus Erythematosus - Drug Profile
    • TAB-08 - Drug Profile
    • TAK-079 - Drug Profile
    • TAK-114 - Drug Profile
    • TAM-01 - Drug Profile
    • ustekinumab - Drug Profile
    • Vaccine for Systemic Lupus Erythematosus - Drug Profile
    • Vaccine to Target IFN-Alpha for Chronic Viral Infections, Dermatomyositis and Systemic Lupus Erythematosus - Drug Profile
    • venetoclax - Drug Profile
    • VISTA-Ig - Drug Profile
    • XmAb-5871 - Drug Profile
    • Y-27 - Drug Profile
  • Systemic Lupus Erythematosus - Recent Pipeline Updates
  • Systemic Lupus Erythematosus - Dormant Projects
  • Systemic Lupus Erythematosus - Discontinued Products
  • Systemic Lupus Erythematosus - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Systemic Lupus Erythematosus, H1 2016
  • Number of Products under Development for Systemic Lupus Erythematosus - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by 4SC AG, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by AbbVie Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Ablynx NV, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by ACEA Biosciences, Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Actelion Ltd, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by AiCuris GmbH & Co. KG, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Alpha Cancer Technologies Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Amgen Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Anthera Pharmaceuticals, Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by arGEN-X BV, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Argos Therapeutics, Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Astellas Pharma Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Baxalta Incorporated, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Biogen, Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Biotest AG, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Celgene Corporation, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Eisai Co., Ltd., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Eli Lilly and Company, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Genosco, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Genovax S.r.l., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by ImmuNext, Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Immungenetics AG, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Immunomedics, Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Invion Limited, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Johnson & Johnson, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by K-Stemcell Co., Ltd., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Kadmon Corporation, LLC, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by LSK BioPartners, Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by MacroGenics, Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by MedAnnex Ltd, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by MedImmune, LLC, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Neovacs SA, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Nippon Chemiphar Co., Ltd., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Plexxikon Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Principia Biopharma Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by RedHill Biopharma Ltd., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Redx Pharma Plc, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Resolve Therapeutics, LLC, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Sanofi, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Sarepta Therapeutics, Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by SBI Biotech Co., Ltd., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Seattle Genetics, Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Stemline Therapeutics, Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by TheraMAB LLC, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Therapix Biosciences Ltd, H1 2016
  • Systemic Lupus Erythematosus - Pipeline by UCB S.A., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by Xencor, Inc., H1 2016
  • Systemic Lupus Erythematosus - Pipeline by XTL Biopharmaceuticals Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Systemic Lupus Erythematosus Therapeutics - Recent Pipeline Updates, H1 2016
  • Systemic Lupus Erythematosus - Dormant Projects, H1 2016
  • Systemic Lupus Erythematosus - Dormant Projects (Contd..1), H1 2016
  • Systemic Lupus Erythematosus - Dormant Projects (Contd..2), H1 2016
  • Systemic Lupus Erythematosus - Dormant Projects (Contd..3), H1 2016
  • Systemic Lupus Erythematosus - Dormant Projects (Contd..4), H1 2016
  • Systemic Lupus Erythematosus - Dormant Projects (Contd..5), H1 2016
  • Systemic Lupus Erythematosus - Discontinued Products, H1 2016
  • Systemic Lupus Erythematosus - Discontinued Products (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for Systemic Lupus Erythematosus, H1 2016
  • Number of Products under Development for Systemic Lupus Erythematosus - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top